Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Impact of p53 Disruption on Mantle Cell Lymphoma (MCL) Treatment out-Come, Multi-Centre Retrospective Study

Ezzat Elhassadi, Brian Hennessy, Senthil Kumar, Louise Sutton, Michelle Griffin, Osasere Osarhieme, Rehman Faryal, Christine Schilling, Mutaz Nur, Eimear Lee, Ramadan Shatwan, Anne Marie Quinn, Mark Catherwood, Amjad Hayat

Blood (2021) 138 (Supplement 1): 4514.

https://doi.org/10.1182/blood-2021-149653

Published: 2021

Journal Articles

A Validated and Licensed Method of Bone Marrow Aspirate Procurement to Support Advanced Therapy Investigational Medicinal Product (ATIMP) Manufacture

Sean Naughton, BSc, MSc, Veronica McInerney, PhD, Sara-Azhari Mohamed, MD, Sara Finnerty, Margaret Tarpey, BSc, MSc, Amjad Hayat, MBBS, MRCP, PhD FRCPath, Janusz Krawczyk, MD

Blood (2017) 130 (Supplement 1): 5460.

https://doi.org/10.1182/blood.V130.Suppl_1.5460.5460

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD

Blood (2016) 128 (22): 3237.

https://doi.org/10.1182/blood.V128.22.3237.3237

Published: 2016

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD

Blood (2015) 126 (23): 4060.

https://doi.org/10.1182/blood.V126.23.4060.4060

Published: 2015

Journal Articles

Detection of Mutations in SF3B1 in Chronic Lymphocytic Leukaemia Patients By Reverse Transcription (Rt) Polymerase Chain Reaction and High Resolution Melt Curve Analysis, an Alternative Approach to Next Generation Sequencing for Routine Molecular Diagnostic Laboratories?

Fiona M Quinn, PhD, Deirdre Waldron, M.Sc., David O'Brien, FAMLs, Johanna Kelly, BSc, Kathleen Scott, PhD, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Elisabeth A. Vandenberghe, MB, PhD

Blood (2015) 126 (23): 5283.

https://doi.org/10.1182/blood.V126.23.5283.5283

Published: 2015

Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath

Blood (2014) 124 (21): 711.

https://doi.org/10.1182/blood.V124.21.711.711

Published: 2014

Journal Articles

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Joy Buckley, M.Sc. B.Sc., Janusz Krawczyk, MD MRCP, Fionnuala Ni Chonchubhair, MSc, BSc., Nelly Besson, PhD, Margaret Tarpey, MSc. BSc., Margaret Murray, MD, F.R.C.Path., F.R.C.P.I. F.F.Path, M.R.C.P. (U.K.), Michael C O'Dwyer, MD FRCPI, FRCPath, Amjad Hayat, MBBS, MRCP, MRCPath, PhD

Blood (2014) 124 (21): 3848.

https://doi.org/10.1182/blood.V124.21.3848.3848

Published: 2014

Journal Articles

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Janusz Krawczyk, MD, MRCP, Sahar Khan, Bushra Ahsan, Larissa Higgins, Enda McGowan, Safa Eltom, Khalid Awad Saeed, Carmelita Gibbons, Karen Maloney, Teresa Meenaghan, Geraldine Walpole, Catriona Collins, Robert Snedker, Moutaz Abdelrahmen, Amjad Hayat, MBBS, PhD, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Margaret Murray, MD, MRCPath, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 5396.

https://doi.org/10.1182/blood.V122.21.5396.5396

Published: 2013

Journal Articles

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Amjad Hayat, MBBS, PhD, David O'Brien, Fiona Quinn, PhD, Fionnuala Keane, PhD, Imelda Parker, PhD, Johanna Kelly, BSc, Marzena Wieczorkowska, Gerard Crotty, MD, Maeve Leahy, MD, Helen Enright, MD, Brian Hennessy, MD, Mary Cahill, MB, Elisabeth A. Vandenberghe, MB, PhD

Blood (2012) 120 (21): 1791.

https://doi.org/10.1182/blood.V120.21.1791.1791

Published: 2012

Journal Articles

Laborartory Medicine Resource Management in Times of Austerity: An Opportunity to Rationalize Services Using Vitamin B12 and Folate Testing As an Example

Maeve P Crowley, MB BCh BAO BSc MRCPI, Margaret Murray, MD, MRCPath, Amjad Hayat, MBBS, PhD

Blood (2012) 120 (21): 4229.

https://doi.org/10.1182/blood.V120.21.4229.4229

Published: 2012

Journal Articles

PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL.

Alessandro Natoni, PhD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Alessia Montagnoli, PhD, Grace Callagy, MB, PhD, MRCPI, FRCPath, Afshin Samali, PhD, Corrado Santocanale, PhD, Michael C O'Dwyer, MD, FRCPI, FRCPath

Blood (2009) 114 (22): 2366.

https://doi.org/10.1182/blood.V114.22.2366.2366

Published: 2009

NARROW

Impact of p53 Disruption on Mantle Cell Lymphoma (MCL) Treatment out-Come, Multi-Centre Retrospective Study

A Validated and Licensed Method of Bone Marrow Aspirate Procurement to Support Advanced Therapy Investigational Medicinal Product (ATIMP) Manufacture

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Detection of Mutations in SF3B1 in Chronic Lymphocytic Leukaemia Patients By Reverse Transcription (Rt) Polymerase Chain Reaction and High Resolution Melt Curve Analysis, an Alternative Approach to Next Generation Sequencing for Routine Molecular Diagnostic Laboratories?

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Minimal Residual Disease Stratification in Fludarabine Ccyclophosphamide Rituximab (FCR) Therapy in Chronic Lymphocytic Leukaemia (CLL

Laborartory Medicine Resource Management in Times of Austerity: An Opportunity to Rationalize Services Using Vitamin B12 and Folate Testing As an Example

PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only